We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Innova for Falsifying COVID-19 Test Data, GMP Lapses
FDA Warns Innova for Falsifying COVID-19 Test Data, GMP Lapses
The FDA issued a warning letter to Innova Medical Group in Pasadena, California for false and misleading labeling for its SARS-CoV-2 antigen rapid qualitative test, as well as marketing the test without FDA clearance and a slew of GMP observations at two facilities.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor